RxDoctor Payments Data

Jesse Dunkle, MD

Internal Medicine · Austin, TXNPI 1811384167

Payments from drug & device makers

$1,177in general payments, 2019–2025

Across 35 payments — averaging $33.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$300
  • Viiv Healthcare Company$241
  • Lilly USA, LLC$196
  • Amgen$121
  • Janssen Products, LP$100
  • Gilead$52
  • plus $167 from 8 others

What the payments were for

  • Food & beverage$1,07792%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$80,303
Medicare patients
250
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$33,148
EliquisApixaban19$25,743
MounjaroTirzepatide13$12,750
SymbicortBudesonide/Formoterol Fumarate19$4,201
Atorvastatin Calcium231$1,699
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,656
Losartan Potassium159$1,428
Amlodipine Besylate180$1,320
Rosuvastatin Calcium92$1,254
Metoprolol Succinate60$1,117
Gabapentin71$1,097
Levothyroxine Sodium100$1,079
Lisinopril151$1,015
Potassium Chloride37$955
Tamsulosin Hcl51$853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$300$33,14835 claims
Lilly USA, LLCMounjaro$196$12,75013 claims
AstraZenecaSymbicort$15$4,20119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →